Group 1 - The innovative drug sector has shown positive market performance this year, with a peak in the number of pharmaceutical-themed funds reported by public institutions in the second quarter, totaling approximately 30 products, which is comparable to the total number of pharmaceutical-themed funds established in 2024 [1] - Penghua Fund's "Yao Mei Hao" series has successfully entered a "harvest season" by employing a dual strategy of passive index investment and active equity management, allowing investors to embrace beta and capture alpha [1][5] Group 2 - The passive index products within the "Yao Mei Hao" series include various ETFs that cover multiple markets and sectors, such as the Penghua Hong Kong Medicine ETF, which has achieved a total net value growth rate of 58.89% over the past year [2] - The Penghua Shanghai Stock Exchange Science and Technology Innovation Board Biomedicine ETF is particularly noteworthy, aligning with the national strategy for technological self-reliance, as the market reassesses the value of innovation capabilities in the pharmaceutical industry [3] Group 3 - In the active equity sector, Penghua Fund has launched several products, including the Penghua Medical Care and Penghua Pharmaceutical Technology funds, with the latter achieving a net value growth rate of 56.40% in the past year [4] - The fund manager emphasizes the competitive landscape of innovative drugs in oncology, noting that Chinese innovative drugs are now on par with leading global standards, with expectations of gaining a competitive edge over the next two to three years [4] Group 4 - Penghua Fund's "Yao Mei Hao" series exemplifies a new investment paradigm in the pharmaceutical sector, combining active equity and passive index strategies, thereby supporting the pharmaceutical industry's development and illustrating the profound concept of "financial support for the real economy" [5]